{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:46:01Z","timestamp":1789854361723,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11255-020-02680-y","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T18:02:51Z","timestamp":1604685771000},"page":"725-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of mizoribine pulse therapy in adult membranous nephropathy"],"prefix":"10.1007","volume":"53","author":[{"given":"Xichao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"5","key":"2680_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2215\/CJN.07570712","volume":"8","author":"Y Chen","year":"2013","unstructured":"Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A (2013) Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 8(5):787\u2013796","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2680_CR2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00467-013-2553-1","volume":"28","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga S, Endo A, Ohtomo Y, Ohtsuka Y, Shimizu T (2013) Uncertainty in management of childhood-onset idiopathic nephrotic syndrome: is the long-term prognosis really favorable? Pediatr Nephrol 28(12):2235\u20132238","journal-title":"Pediatr Nephrol"},{"key":"2680_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lfs.2016.04.012","volume":"154","author":"X Wang","year":"2016","unstructured":"Wang X, Song X, Liu Y, Zhang W, An W, Tu Y (2016) Treatment of membranous nephropathy with mizoribine: a control trial. Life Sci 154:75\u201378","journal-title":"Life Sci"},{"issue":"6","key":"2680_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10157-016-1340-2","volume":"21","author":"T Saito","year":"2017","unstructured":"Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, Nishi S, Yoshimura A, Sato H, Ogahara S, Sasatomi Y, Kataoka Y, Ueda S, Koyama A, Maruyama S, Nangaku M, Imai E, Matsuo S, Tomino Y, Refractory nephrotic syndrome study group (2017) Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. Clin Exp Nephrol 21(6):961\u2013970","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"2680_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/iju.13476","volume":"25","author":"T Nishioka","year":"2018","unstructured":"Nishioka T, Yoshimura N, Ushigome H, Watarai Y, Nishimura K, Akioka K, Nakamura N, Kawakita M, Yuzawa K, Nakatani T (2018) High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: a Japanese multicenter study. Int J Urol 25(2):141\u2013145","journal-title":"Int J Urol"},{"issue":"1","key":"2680_CR6","first-page":"40","volume":"78","author":"M Fujieda","year":"2012","unstructured":"Fujieda M, Ishihara M, Morita T, Hayashi A, Okada S, Ohta T, Sakano T, Wakiguchi H (2012) Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 78(1):40\u201346","journal-title":"Clin Nephrol"},{"issue":"2","key":"2680_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10157-018-1628-5","volume":"23","author":"A Mizutani","year":"2019","unstructured":"Mizutani A, Fujinaga S, Sakuraya K, Hirano D, Shimizu T (2019) Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol 23(2):244\u2013250","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2680_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-Type phospholipase A (sub 2) receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med 361(1):11\u201321","journal-title":"New Engl J Med"},{"issue":"1","key":"2680_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"274","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H (2000) Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 274(1):87\u201392","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2680_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2125.2006.02779.x","volume":"63","author":"D Stypinski","year":"2007","unstructured":"Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H (2007) Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 63(4):459\u2013468","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2680_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12882-018-1033-z","volume":"19","author":"T Hama","year":"2018","unstructured":"Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC) (2018) Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial). BMC Nephrol 19(1):223","journal-title":"BMC Nephrol."},{"issue":"1","key":"2680_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.transproceed.2016.11.015","volume":"49","author":"K Akioka","year":"2017","unstructured":"Akioka K, Ishikawa T, Osaka M, Kadotani Y, Okugawa K, Nakano K, Osaka Y, Tsuchiya K, Sako H (2017) Hyperuricemia and acute renal failure in renal transplant recipients treated with high-dose mizoribine. Transplant Proc 49(1):73\u201377","journal-title":"Transplant Proc"},{"issue":"9","key":"2680_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/molecules24091723","volume":"24","author":"SF Li","year":"2019","unstructured":"Li SF, Gong MJ, Sun YF, Shao JJ, Zhang YG, Chang HY (2019) In vitro and in vivo antiviral activity of mizoribine against foot-and-mouth disease virus. Molecules 24(9):1723. https:\/\/doi.org\/10.3390\/molecules24091723","journal-title":"Molecules."}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-020-02680-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T14:11:01Z","timestamp":1617891061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-020-02680-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02680-y","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}